1. No category

Stanford Cancer Center
Click here to print
Click here to print
this page (PDF)
this page (PDF)
Lymphoma CRG
5 May 2015
Mycosis Fungoides
Stage IIB
Indolent Disease
Failed Systemic
Therapy only
Failed both
Methotrexate and
Bexarotene
LYMNHL0095
Phase III Brentuximab
Vedotin (SGN-35) vs
Physician's Choice
(Methotrexate/
Bexarotene) in CD30+
CTCL
LYMNHL0103
Phase III Safety and
Efficacy of E7777
(Denileukin Diftitox) in
Persistent/Recurrent
Cutaneous NHL
PI: Kim
Millennium Pharmaceuticals
Aggressive Disease
LYMNHL0118
Phase II MK-3475
in the Treatment of
Relapsed/
Refractory Mycosis
Fungoides/Sezary
Syndrome
PI: Kim
CITN
PI: Kim
Esai Oncology Franchise
Failed Control Arm
Failed
Systemic
Therapy/topical
No prior
Romidepsin
LYMNHL0127
Phase I DoseEscalation
Carfilzomib +/Romidepsin in
Cutaneous T-Cell
Lymphoma
LYMNHL0103
Phase III Safety
and Efficacy of
E7777 (Denileukin
Diftitox) in
Persistent/
Recurrent
Cutaneous NHL
PI: Kim
Eisai Oncology
Franchise
- Large Cell
Transformation (LCT)
LYMNHL0099
Phase III Monoclonal
Antibody KW-0761
(Mogamulizumab) Vs
Vorinostat in
Cutaneous T-Cell
Lymphoma
PI: Kim
Kyowa Hakko Kirin
Pharma
PI: Kim
Pending
LYMNHL0095-EX
Treatment-Option
Brentuximab Vedotin in
Progression of HD or
Systemic Anaplastic Large
Cell Lymphoma
PI: Kim
Seattle Genetics
KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Extension Study
Trial Posting
Enrollment on Hold
Pleasemark
markup
upaacopy
copyusing
usingblack
blackink
inkand
andfax
faxchanges
changesto
to725-9204
736-2558
Please